Olverembatinib (HQP1351)
POLARIS-3
Ascentage Pharma · Phase 3 · Recruiting · Enrollment 40
| Arm | Reported safety |
|---|
A count stays a count. This page does not turn a count into a percent.
GIST
Programs, trials, and reported response and survival for gastrointestinal stromal tumor.
Olverembatinib (HQP1351)
Ascentage Pharma · Phase 3 · Recruiting · Enrollment 40
| Arm | Reported safety |
|---|
A count stays a count. This page does not turn a count into a percent.